Written by a model from the transcript; not yet reviewed.
Perimenopause affects over four billion people globally, yet it has historically been neglected by medical science. In this episode, the host speaks with two leading endocrinologists, Dr. Nanette Santoro and Dr. Genevieve Neill Perry, to unpack the physiological and neurological changes occurring during the menopause transition, the history of hormone replacement therapy, and the recent explosion of commercialized treatments and unverified claims on social media.
The guests explain the biological mechanisms behind hot flashes—focusing on hyperactive candy neurons in the brain—and discuss data from long-term initiatives like the SWAN study. They argue that while hormone therapy is a valuable, underutilized tool for managing specific symptoms like hot flashes and sleep disturbances when prescribed correctly, it is not a panacea or a fountain of youth. The conversation emphasizes that midlife women are increasingly targeted by commercial interests promoting unproven therapies, such as unregulated peptides and testosterone, requiring patients and providers to rely on rigorous scientific evidence rather than social media hype.
The host introduces the episode and explains perimenopause, its prevalence, and the growing public conversation.
Host shares her own recent experience starting estrogen and progesterone and its effects on energy and mood.
Hosts introduce Dr. Nanette Santoro and Dr. Genevieve Neill‑Perry and outline their long‑term research projects.
Experts describe the growing momentum in perimenopause research and the need for more information.
Explanation of hormonal fluctuations, body‑wide changes, and variability in symptom severity.
Discussion of why some women never recover from hot flashes and the dynamic hormonal environment.
Neuroscientific explanation of hot flashes, including candy neurons and neurokinin release.
Experts caution against blaming all symptoms on perimenopause and highlight the need for individualized assessment.
Overview of the Women's Health Initiative, its findings, and how misinterpretation led to a decline in hormone therapy use.
Long‑term follow‑ups show reduced risks for certain age groups, leading to a cautious resurgence in prescribing.
Experts warn against treating hormones as a cure‑all and discuss commercialization pressures.
Hosts thank the experts, recap key points, and provide episode credits and contact info.
Decades of Study on Hormonesinsight
Dr. Nanette Santoro and Dr. Genevieve Neill Perry are introduced as pioneers leading long-term studies on perimenopause and hormone therapy effects.
Not Just Slowing Downinsight
Hormones do not simply peter out quietly; instead, perimenopause involves wild fluctuations across a body-wide set of changes.
The Brain Mechanism of Flashesinsight
Neuroin peptide pathways in the brain drive hot flashes as neurons become hyperactive due to dropping and fluctuating estrogen.
The Impact of the WHIdebate
The Women's Health Initiative study on older women was improperly generalized to all menopausal and perimenopausal patients, causing prescriptions to plummet.
Revisiting WHI Follow-Up Datadata
Long-term follow-up studies revealed no net change in mortality and a more favorable risk-benefit profile for women aged 50 to 60.
Commercialization of Midlife Womeninsight
Midlife women have become a prime market for commercial products, leading to an onslaught of unverified health claims online.
The Testosterone Crazeinsight
Despite a virtual craze for testosterone as a treatment, existing clinical studies fail to support its use for many requested indications.
“Perimenopause, the window before menopause where hormones begin fluctuating wildly, leaving women with brain fog, hot flashes, dropping bone density, and mood changes.”
“The neurons are called candy neurons, you know?”
“I have concern about hormones being the answer to everything. Much as I love hormones and have dedicated my life to studying them, they're not the answer to everything.”
After decades of controversy over prescribing hormone therapy for perimenopause, many providers are reconsidering their approach.
2,945 words · 6 speakers
Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.
Page updated · transcript and summary are machine-generated